Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Common Equity (2021 - 2025)

Historic Common Equity for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$4.3 million.

  • Lyra Therapeutics' Common Equity fell 12099.03% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year decrease of 12099.03%. This contributed to the annual value of $11.6 million for FY2024, which is 8703.42% down from last year.
  • Latest data reveals that Lyra Therapeutics reported Common Equity of -$4.3 million as of Q3 2025, which was down 12099.03% from $1.6 million recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Common Equity high stood at $106.2 million for Q2 2022, and its period low was -$4.3 million during Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $57.5 million (2021), whereas its average is $52.1 million.
  • Per our database at Business Quant, Lyra Therapeutics' Common Equity soared by 18417.68% in 2023 and then crashed by 12099.03% in 2025.
  • Lyra Therapeutics' Common Equity (Quarter) stood at $34.3 million in 2021, then surged by 135.32% to $80.8 million in 2022, then grew by 10.73% to $89.4 million in 2023, then crashed by 87.03% to $11.6 million in 2024, then crashed by 137.33% to -$4.3 million in 2025.
  • Its last three reported values are -$4.3 million in Q3 2025, $1.6 million for Q2 2025, and $3.9 million during Q1 2025.